

RESEARCH MONOGRAPH . COMPOUND PROFILE

Suzetrigine

A first-in-class, peripherally restricted NaV1.8 sodium channel inhibitor developed by Vertex Pharmaceuticals as a non-opioid analgesic for moderate-to-severe acute pain, distinguished by allosteric binding to voltage-sensing domain 2 and greater than 31,000-fold selectivity over all other sodium channel subtypes.

DOCUMENT	KDC-MN-1576
ISSUED	2026-05-20
REVISION	1.0
AUTHOR	Kodi <i>ac</i> biolabs Research
COMPOUND CLASS	Selective NaV1.8 voltage-gated sodium channel inhibitor (non-opioid peripheral analgesic)

ABSTRACT

Suzetrigine (VX-548; trade name Journavx) is the first selective inhibitor of the NaV1.8 voltage-gated sodium channel to receive regulatory approval, granted by the United States Food and Drug Administration on 30 January 2025 for the treatment of moderate-to-severe acute pain in adults. The compound represents a mechanistically novel analgesic class, acting by allosteric binding to the extracellular S3-S4 loop of voltage-sensing domain 2 (VSD2) of the NaV1.8 channel, where a KKGS amino acid sequence unique to this subtype confers greater than 31,000-fold selectivity over the other nine human voltage-gated sodium channel isoforms. NaV1.8, encoded by the SCN10A gene, is expressed almost exclusively in peripheral nociceptive neurons of the dorsal root ganglia, where it contributes more than 70 percent of the depolarizing current during pain-signaling action potentials. Suzetrigine stabilizes the channel in its closed (resting) state through tonic inhibition that is independent of channel opening frequency, thereby reducing pathological nociceptor hyperexcitability without affecting cardiac, central nervous system, or skeletal muscle sodium channels.

The compound emerged from a multi-year medicinal chemistry program at Vertex Pharmaceuticals that progressed through the predecessors VX-128 and VX-150 before arriving at VX-548, which demonstrated an in vitro IC₅₀ of 0.68 nanomolar against human NaV1.8 with negligible activity (IC₅₀ greater than 10,000 nanomolar) against all other NaV subtypes. In Phase 2 randomized controlled trials in postoperative bunionectomy and abdominoplasty pain, suzetrigine at a 100 mg loading dose

followed by 50 mg every 12 hours produced statistically significant reductions in the time-weighted sum of pain intensity difference over 48 hours (SPID48) compared to placebo (37.8-point and 36.8-point superiority, respectively). In the pivotal Phase 3 NAVIGATE-1 (bunionectomy, N = 1,073) and NAVIGATE-2 (abdominoplasty, N = 1,118) trials, suzetrigine achieved statistically significant superiority over placebo on SPID48 ($p = 0.0002$ and $p < 0.0001$, respectively), with analgesic efficacy broadly comparable to hydrocodone/acetaminophen but without opioid-class adverse effects including respiratory depression, sedation, or abuse liability.

Pharmacokinetics are characterized by oral administration with a time to peak plasma concentration of approximately 3 hours in the fasted state, extensive tissue distribution (volume of distribution approximately 495 liters), 99 percent plasma protein binding, and hepatic metabolism predominantly through CYP3A enzymes to the active metabolite M6-SUZ (3.7-fold less potent than parent compound). The terminal elimination half-life of suzetrigine is 23.6 hours, and that of M6-SUZ is 33.0 hours, supporting twice-daily maintenance dosing. Excretion occurs through both fecal (49.9 percent) and urinary (44.0 percent) routes. The compound is contraindicated with strong CYP3A4 inhibitors and in severe hepatic impairment (Child-Pugh Class C). The most common adverse events in clinical trials were nausea, headache, dizziness, constipation, pruritus, muscle spasms, and rash, all predominantly mild to moderate in severity. No respiratory depression, physical dependence, or abuse potential has been identified in clinical or preclinical assessments.

This monograph documents the chemistry, structural pharmacology, mechanism of action, comprehensive

pharmacokinetics, preclinical and clinical evidence base, regulatory history, sourcing and handling considerations, drug interaction profile, adverse-event signal, and a structured comparative assessment of five alternative analgesic approaches (VX-150, hydrocodone/acetaminophen, pregabalin, celecoxib, and lidocaine 5% patch) against suzetrigine on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

International Nonproprietary Name: Suzetrigine.

Trade name: Journavx (Vertex Pharmaceuticals; United States).

Development codes: VX-548, VX548. The development code VX-548 is the canonical identifier in the clinical trial literature and the pharmacology publications preceding the FDA approval [1, 2].

Chemical Abstracts Service registry number: 2649467-58-1.

International Union of Pure and Applied Chemistry name: 4-[[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)oxolane-2-carbonyl]amino]pyridine-2-carboxamide.

1.2 Structural class and chemistry

Suzetrigine is a substituted tetrahydrofuran (oxolane) bearing a difluoromethoxyphenyl substituent, a trifluoromethyl group, and a pyridinecarboxamide pharmacophore linked through an amide bond. The structural class is novel; it does not belong to traditional analgesic families (opioids, nonsteroidal anti-inflammatory drugs, anticonvulsants, local anesthetics) and represents a purpose-designed sodium channel modulator scaffold optimized through iterative medicinal chemistry at Vertex Pharmaceuticals.

Molecular formula: C₂₁H₂₀F₅N₃O₄.

Molecular weight: 473.40 g/mol.

Physical properties: The compound is supplied as a white to off-white crystalline solid. Oral bioavailability in humans has not been published as an absolute value but is sufficient for clinical efficacy at the approved 50 to 100 mg oral dose range. The compound demonstrates sex-dependent bioavailability in rats (96 percent in

females versus 11 percent in males), though this species-specific difference does not translate to clinically meaningful sex differences in human pharmacokinetics at approved doses.

Stereochemistry: Suzetrigine contains four stereocenters at the 2, 3, 4, and 5 positions of the oxolane ring, configured as (2R,3S,4S,5R). The compound is manufactured and supplied as a single stereoisomer. The stereochemical configuration is critical for the binding interaction with the VSD2 pocket of NaV1.8; other diastereomers show substantially reduced potency.

1.3 Synthesis

The published synthesis of suzetrigine proceeds through a multi-step route covered by Vertex Pharmaceuticals international patent WO2022/256660 (application date 3 June 2022, publication date 8 December 2022). The patent describes methods characterized as high-efficiency, simple, and economical for the preparation of the final compound. The synthesis involves construction of the substituted tetrahydrofuran core with defined stereochemistry, introduction of the 3,4-difluoro-2-methoxyphenyl substituent, and coupling of the oxolane carboxylic acid intermediate with the 4-aminopyridine-2-carboxamide pharmacophore through amide bond formation [3]. Precise synthetic details beyond the patent disclosure are proprietary to Vertex Pharmaceuticals. Research-grade suzetrigine is available from chemical suppliers (MedChemExpress, Cayman Chemical, MedKoo Biosciences, BocSci) at greater than 98 percent purity by HPLC.

2. Abstract

Suzetrigine (VX-548; Journavx) is the first approved selective inhibitor of the NaV1.8 voltage-gated sodium channel, representing a mechanistically novel class of non-opioid analgesic for the treatment of moderate-to-severe acute pain in adults [1, 2]. The compound was approved by the United States Food and Drug Administration on 30 January 2025 after receiving breakthrough therapy, fast track, and priority review designations, making it the first non-opioid analgesic in a new mechanism class approved since celecoxib in 1998.

NaV1.8, encoded by the SCN10A gene, is a tetrodotoxin-resistant voltage-gated sodium channel expressed almost exclusively in peripheral nociceptive neurons (small-diameter C-fibers and lightly myelinated A-delta fibers) of the dorsal root ganglia [4]. The channel is responsible for more than 70 percent of the depolarizing current during action potentials in these neurons and is essentially absent from brain and cardiac tissue, providing a clean peripheral-specific target for pain intervention without central nervous system or cardiovascular off-target effects. Human genetic validation is strong: gain-of-function mutations in SCN10A cause painful peripheral neuropathy, while loss-of-function variants are associated with reduced pain sensitivity [5, 6].

Suzetrigine achieves extraordinary selectivity by binding to the extracellular S3-S4 loop of voltage-sensing domain 2 (VSD2), where the KKGS amino acid motif unique to NaV1.8 creates a binding pocket not present in other sodium channel isoforms [7, 8]. The compound demonstrates an IC₅₀ of 0.68 nanomolar against human NaV1.8 with greater than 31,000-fold selectivity over all other voltage-gated sodium channel subtypes (IC₅₀ greater than 10,000 nanomolar for NaV1.1 through NaV1.7 and NaV1.9) [9]. The mechanism is tonic inhibition: suzetrigine stabilizes NaV1.8 in its closed (resting) state, reducing nociceptor excitability without requiring channel opening for drug access. This state-dependent profile differs from traditional use-dependent sodium channel blockers (local anesthetics, anticonvulsants) and confers activity across a wide range of voltages and impulse frequencies characteristic of pathological pain states.

Clinical efficacy was established in two pivotal Phase 3 randomized, double-blind, placebo-controlled and active-comparator-controlled trials (NAVIGATE-1 and NAVIGATE-2) in postoperative acute pain following bunionectomy and abdominoplasty, respectively [10, 11]. Suzetrigine at a 100 mg loading dose followed by 50 mg every 12 hours demonstrated statistically significant superiority over placebo on the primary endpoint (SPID48) in both trials and analgesic efficacy broadly comparable to low-dose hydrocodone/acetaminophen without opioid-class adverse effects. A Phase 3 single-arm study in mixed acute pain (surgical and non-surgical) demonstrated that 83.2 percent of patients rated pain relief as good, very good, or excellent [12].

The compound is well tolerated at approved doses. The most common adverse events are nausea, headache, dizziness, constipation, pruritus, muscle spasms, and rash. No respiratory depression, sedation, physical dependence, or abuse potential has been identified. The pharmacokinetic profile supports twice-daily oral dosing with a 23.6-hour terminal half-life, CYP3A-mediated metabolism, and clinically significant interactions with strong CYP3A4 inhibitors and inducers.

3. Discovery and Development History

3.1 Target identification and rationale

The sodium channel NaV1.8 was identified as a pain target in the late 1990s and early 2000s based on its restricted expression in peripheral nociceptors and its dominant contribution to action potential generation in pain-signaling neurons [4, 5]. Genetic studies in human populations reinforced the target: gain-of-function mutations in SCN10A (the gene encoding NaV1.8) were linked to painful peripheral neuropathy syndromes, while loss-of-function variants conferred reduced pain sensitivity without other neurological deficits [6]. The peripheral restriction of NaV1.8 (absent from brain, heart, and skeletal muscle) offered a theoretical safety advantage over non-selective sodium channel blockers (local anesthetics, carbamazepine, lamotrigine) and over NaV1.7 inhibitors that face challenges in achieving adequate spinal cord penetration.

3.2 Predecessor compounds

Vertex Pharmaceuticals initiated a NaV1.8 inhibitor program that progressed through several clinical candidates before arriving at suzetrigine.

VX-128 was an early clinical candidate that demonstrated analgesic activity in evoked pain models but was terminated in Phase 1 due to dose-limiting skin rash and angioedema [13].

VX-150 was a subsequent NaV1.8-selective inhibitor that advanced through Phase 1 and Phase 2 clinical development. A Phase 1 randomized, double-blind, placebo-controlled crossover study in healthy male adults demonstrated dose-dependent analgesic effects across multiple evoked pain models with favorable pharmacokinetics and mild adverse events (headache, pruritus) [14]. VX-150 completed three positive proof-of-concept Phase 2 studies in patients with acute pain following bunionectomy surgery, osteoarthritis, and small fiber neuropathy. However, VX-150 displayed moderate analgesic potency requiring high doses and was ultimately superseded by VX-548, which demonstrated substantially greater potency at the NaV1.8 target.

A-803467 (Abbott Laboratories) was an earlier NaV1.8 inhibitor that demonstrated preclinical efficacy in models of inflammatory and neuropathic pain but was abandoned due to limited oral bioavailability and suboptimal selectivity [15].

3.3 Development of VX-548 (suzetrigine)

VX-548 emerged from continued medicinal chemistry optimization at Vertex Pharmaceuticals, with the goal of achieving substantially greater potency and selectivity than VX-150 while maintaining oral bioavailability and a favorable safety profile. The compound demonstrated an IC₅₀ of 0.68 nanomolar against human NaV1.8 (approximately 3-fold more potent than VX-150 at the same target) with greater than 31,000-fold selectivity over all other sodium channel subtypes [9]. Preclinical studies in rats and non-human primates revealed no significant adverse effects, no potential for dependence, and no neurobehavioral, cardiovascular, or respiratory effects even at supratherapeutic exposures.

3.4 Clinical development

Vertex advanced VX-548 through a rapid clinical development program:

Phase 2 trials in postoperative acute pain (bunionectomy, NCT04977336, N = 274; abdominoplasty, NCT05034952, N = 303) demonstrated statistically significant pain reduction versus placebo, establishing proof of concept and informing dose selection for Phase 3 [16, 17].

Phase 3 pivotal trials (NAVIGATE-1, NCT05553366; NAVIGATE-2, NCT05558410) were completed in 2024 with positive primary endpoint results [10, 11].

In July 2024, the FDA accepted the New Drug Application for suzetrigine. On 30 January 2025, the FDA granted approval for Journavx (suzetrigine) for the treatment of moderate-to-severe acute pain in adults, conferring breakthrough therapy, fast track, and priority review designations [1].

3.5 Post-approval development

Following the acute pain approval, Vertex is advancing suzetrigine in chronic neuropathic pain indications. A Phase 2 study in painful lumbosacral radiculopathy (NCT06176196, N = 218) did not achieve statistical significance on the primary endpoint at 12 weeks (suzetrigine: -2.02 point NPRS reduction versus placebo: -1.98)

[18]. Phase 3 pivotal trials in painful diabetic peripheral neuropathy (versus pregabalin and placebo) are ongoing. Phase 4 post-marketing studies in multimodal acute perioperative pain therapy are underway as of November 2025.

4. Mechanism of Action

4.1 NaV1.8 channel biology

The voltage-gated sodium channel NaV1.8 is a member of the nine-isoform human NaV family (NaV1.1 through NaV1.9), each encoded by a distinct gene (SCN1A through SCN11A, with NaV1.8 encoded by SCN10A). NaV1.8 is distinguished from the other family members by its tetrodotoxin resistance (IC₅₀ for tetrodotoxin block is approximately 60 micromolar, compared to low nanomolar for NaV1.1 through NaV1.7), its remarkably restricted tissue expression (almost exclusively in peripheral sensory neurons of the dorsal root ganglia and trigeminal ganglia), and its biophysical properties including slow inactivation kinetics and a depolarized voltage dependence of activation [4, 5].

NaV1.8 is responsible for more than 70 percent of the inward sodium current during action potentials in nociceptive C-fiber and A-delta-fiber neurons. The channel enables repetitive firing at the high frequencies characteristic of inflammatory and neuropathic pain states. Knockout studies in mice demonstrate that loss of NaV1.8 function produces marked reduction in inflammatory pain behavior without affecting other sensory modalities [19].

4.2 Binding site and selectivity mechanism

Suzetrigine achieves its extraordinary selectivity through allosteric binding to the extracellular S3-S4 loop of voltage-sensing domain 2 (VSD2) of NaV1.8 [7, 8]. This binding site is structurally and mechanistically distinct from the intracellular local anesthetic binding site in the pore domain (domain IV S6 helix) used by lidocaine, carbamazepine, and other traditional sodium channel blockers.

The selectivity determinant is the KKGS amino acid sequence (lysine-lysine-glycine-serine) present in the VSD2 S3-S4 extracellular loop of NaV1.8 but absent from all other human sodium channel isoforms [7]. Domain-swap experiments between NaV1.2 and NaV1.8 have confirmed that transfer of the NaV1.8 VSD2 region to NaV1.2 confers suzetrigine sensitivity, demonstrating that this domain is both necessary and sufficient for binding [8]. The resulting selectivity ratio is greater than

31,000-fold for NaV1.8 over all other tested sodium channel isoforms (IC₅₀ greater than 10,000 nanomolar for NaV1.1 through NaV1.7 and NaV1.9 versus 0.68 nanomolar for NaV1.8) [9].

4.3 State-dependent inhibition

Suzetrigine is classified as a tonic NaV1.8 inhibitor that preferentially stabilizes the channel in its closed (resting) state [8, 9]. This mechanism differs fundamentally from the use-dependent (frequency-dependent) block produced by local anesthetics and anticonvulsant sodium channel blockers, which preferentially bind to and stabilize the inactivated state and show increased block with higher firing frequency.

Suzetrigine exhibits what has been termed "reverse use-dependence": the compound shows dramatic relief of inhibition upon membrane depolarization, suggesting greatly reduced affinity for channels with voltage sensors in a depolarized (activated) position [8]. The time constant of this relief is approximately 40 milliseconds. The practical consequence is that suzetrigine provides sustained tonic inhibition of pathologically hyperexcitable nociceptors (which spend substantial time in the resting state between bursts) while having reduced effect on channels that are continuously depolarized.

4.4 Downstream analgesic mechanism

By stabilizing NaV1.8 in its closed state, suzetrigine reduces the probability of channel opening in response to depolarizing stimuli in peripheral nociceptors. This reduces action potential generation and propagation along pain-signaling fibers projecting from peripheral injury sites to the dorsal horn of the spinal cord. The peripheral site of action (dorsal root ganglia and peripheral nerve terminals) means that pain signal inhibition occurs before ascending transmission to the central nervous system, reducing both the sensory and affective components of pain perception without affecting central processing, motor function, or autonomic regulation [20].

The absence of NaV1.8 expression in the central nervous system, cardiac tissue, and skeletal muscle provides the mechanistic basis for the favorable safety profile: no respiratory depression (brainstem sodium channels are NaV1.1 and NaV1.6), no

sedation (cortical channels are NaV1.1, NaV1.2, and NaV1.6), no cardiac conduction disturbance (cardiac channels are NaV1.5), and no motor weakness (skeletal muscle channels are NaV1.4) [4].

5. Pharmacokinetics and Routes of Administration

5.1 Absorption

Suzetrigine is administered orally as 50 mg tablets. The recommended regimen is a 100 mg loading dose on an empty stomach (at least one hour before or two hours after eating) followed by 50 mg every 12 hours, which may be taken with or without food after the initial dose [1].

Time to peak plasma concentration (T_{max}) is approximately 3 hours in the fasted state; administration with a high-fat meal delays T_{max} to approximately 5 hours without substantially altering total exposure [21]. The loading dose is taken on an empty stomach to avoid delayed onset of analgesia. Maximum plasma concentration (C_{max}) at steady state is 0.62 micrograms per milliliter.

5.2 Distribution

Suzetrigine has extensive tissue distribution with a volume of distribution of approximately 495 liters, indicating substantial partitioning into peripheral tissues including the target nociceptive neurons [21]. Plasma protein binding is approximately 99 percent for the parent compound and 96 percent for the active metabolite M6-SUZ. Central nervous system penetration is minimal, consistent with the peripheral mechanism of action and the absence of sedation or cognitive effects at therapeutic doses.

5.3 Metabolism

Suzetrigine is metabolized primarily in the liver through CYP3A-mediated oxidative pathways [21]. The principal active metabolite is M6-SUZ, which demonstrates approximately 3.7-fold lower potency against NaV1.8 than the parent compound. M6-SUZ achieves higher steady-state plasma concentrations than the parent (AUC_{0-24h} of 34.7 micrograms times hours per milliliter for M6-SUZ versus 11.5 for suzetrigine; C_{max} of 1.5 micrograms per milliliter for M6-SUZ versus 0.62 for suzetrigine), contributing to overall analgesic activity.

Suzetrigine also acts as a CYP3A4 inducer, which is clinically relevant for drug-drug interactions with sensitive CYP3A4 substrates including certain hormonal contraceptives.

5.4 Elimination

The terminal elimination half-life is 23.6 hours for suzetrigine and 33.0 hours for M6-SUZ, supporting the twice-daily maintenance dosing regimen [21]. Apparent clearance is 13.9 liters per hour.

Excretion occurs through dual pathways: 49.9 percent fecal (with 9.1 percent as unchanged parent compound) and 44.0 percent urinary (primarily as metabolites). The balanced fecal and urinary elimination reduces the impact of isolated hepatic or renal impairment on drug exposure.

5.5 Special populations

Hepatic impairment: Mild hepatic impairment (Child-Pugh Class A) does not require dose adjustment. Moderate hepatic impairment (Child-Pugh Class B) increases AUC approximately 1.5-fold and Cmax approximately 1.3-fold; dose adjustment to 50 mg every 24 hours after the fifth dose is recommended. Severe hepatic impairment (Child-Pugh Class C) is a contraindication [1].

Renal impairment: Mild to moderate renal impairment does not require dose adjustment. Phase 2 neuropathic pain trials have noted dose-dependent effects on creatinine clearance at higher doses; close renal monitoring is recommended in chronic dosing contexts [18].

Sex and age: No clinically meaningful sex differences in pharmacokinetics have been identified in human studies at approved doses, despite the dramatic sex difference observed in rat bioavailability. Geriatric pharmacokinetics have not demonstrated clinically significant differences requiring dose adjustment.

Pregnancy and lactation: Suzetrigine is contraindicated in pregnancy due to the inability to exclude teratogenic risk. Lactation data are not available.

5.6 Routes of administration

Suzetrigine is formulated exclusively as oral tablets (50 mg) for the approved indication. No intravenous, intramuscular, or topical formulations are currently available or in development.

6. Preclinical Pharmacology

6.1 In vitro pharmacology

Suzetrigine demonstrates an IC₅₀ of 0.68 nanomolar (plus or minus 0.16 nanomolar) against human NaV1.8 expressed in heterologous cell systems [9]. At a concentration of 200 nanomolar, the compound effectively blocks NaV1.8-mediated sodium currents in vitro. Selectivity profiling against a panel of eight additional voltage-gated sodium channel isoforms (NaV1.1 through NaV1.7, NaV1.9) demonstrated IC₅₀ values exceeding 10,000 nanomolar for all, yielding the greater than 31,000-fold selectivity ratio that distinguishes suzetrigine from all prior sodium channel-targeting analgesics [9].

Electrophysiological characterization confirms that suzetrigine produces tonic (resting-state) inhibition with reverse use-dependence: the compound binds preferentially to the closed channel configuration and shows relief of block upon sustained membrane depolarization [8]. This is mechanistically distinct from the use-dependent block of local anesthetics and anticonvulsants (lidocaine, carbamazepine, lacosamide) that preferentially bind to inactivated channel states and show increased block with repetitive firing.

6.2 In vivo efficacy

Preclinical studies in rodent and non-human primate models demonstrated significant reductions in nociceptive behaviors across inflammatory and neuropathic pain paradigms [13, 20]. Suzetrigine reduced mechanical and thermal hyperalgesia in models of inflammatory pain (complete Freund's adjuvant), neuropathic pain (chronic constriction injury, spinal nerve ligation), and capsaicin-induced secondary mechanical allodynia.

6.3 Safety pharmacology

Preclinical safety pharmacology assessments in rats and cynomolgus monkeys revealed no significant neurobehavioral, cardiovascular, or respiratory adverse effects at supratherapeutic exposures [13, 20]. Central nervous system assessment

(functional observational battery, locomotor activity) showed no effects at doses producing plasma concentrations many-fold above the human therapeutic range. Cardiovascular assessment (hERG channel assay, telemetered non-human primates) showed no QT prolongation or conduction abnormalities at therapeutic exposures. Respiratory assessment demonstrated no respiratory depression at any tested dose, consistent with the absence of NaV1.8 from brainstem respiratory centers.

6.4 Abuse liability assessment

Standard preclinical abuse liability assessments (drug self-administration, conditioned place preference, drug discrimination) demonstrated no rewarding properties or abuse potential for suzetrigine, consistent with its peripheral mechanism of action and minimal central nervous system penetration [20].

7. Clinical Evidence Base

7.1 Phase 2 acute pain trials

Bunionectomy (NCT04977336): A Phase 2 randomized, double-blind, placebo-controlled trial enrolled 274 patients with moderate-to-severe postoperative pain following bunionectomy [16]. Patients were randomized to suzetrigine (100 mg loading dose, then 50 mg every 12 hours), lower-dose suzetrigine, or placebo for 48 hours. The primary endpoint was SPID48. High-dose suzetrigine produced a 37.8-point greater pain reduction versus placebo (statistically significant).

Abdominoplasty (NCT05034952): A Phase 2 randomized, double-blind, placebo-controlled trial enrolled 303 patients with moderate-to-severe postoperative pain following abdominoplasty [17]. The same dosing regimen produced a 36.8-point greater pain reduction versus placebo (statistically significant). Both Phase 2 trials established the 100 mg loading dose followed by 50 mg every 12 hours as the optimal regimen for Phase 3 development.

7.2 Phase 3 pivotal trials (NAVIGATE program)

NAVIGATE-1 (NCT05553366, bunionectomy): A Phase 3 randomized, double-blind, placebo-controlled and active-comparator-controlled trial enrolled 1,073 patients with moderate-to-severe postoperative pain (4 or greater on the 0-10 Numeric Pain Rating Scale) following bunionectomy [10]. Patients were randomized 2:2:1 to suzetrigine, hydrocodone bitartrate 5 mg/acetaminophen 325 mg (HB/APAP) every 6 hours, or placebo. The primary endpoint was SPID48.

Results: The least-squares mean SPID48 was 99.9 for suzetrigine versus 70.6 for placebo (difference 29.3, $p = 0.0002$). The HB/APAP arm achieved a numerically higher SPID48 than suzetrigine (120.1 versus 99.9; difference of 20.2 points favoring HB/APAP), but the trial was not powered for a non-inferiority comparison. Suzetrigine produced clinically meaningful pain reduction within 2 to 4 hours versus 8 hours for placebo.

NAVIGATE-2 (NCT05558410, abdominoplasty): A Phase 3 randomized, double-blind, placebo-controlled and active-comparator-controlled trial enrolled 1,118 patients following abdominoplasty [11]. The same randomization scheme and dosing regimen were used.

Results: The least-squares mean SPID48 was 118.4 for suzetrigine versus 70.1 for placebo (difference 48.4, $p < 0.0001$). The HB/APAP comparison showed a 6.6-point difference ($p = 0.2781$; not statistically significant), demonstrating comparable efficacy between suzetrigine and low-dose opioid combination therapy in this surgical model.

7.3 Phase 3 broad acute pain study

Mixed acute pain (NCT05661734): A Phase 3, open-label, single-arm study enrolled 256 patients experiencing moderate-to-severe acute pain from both surgical and non-surgical etiologies [12]. The study evaluated suzetrigine at the approved dosing regimen for up to 14 days. On the Patient Global Assessment, 83.2 percent of patients rated treatment as good, very good, or excellent. Response rates were 82.0 percent for surgical pain and 91.2 percent for non-surgical pain. Only 1.6 percent of patients discontinued due to lack of efficacy.

7.4 Chronic neuropathic pain investigations

Lumbosacral radiculopathy (NCT06176196): A Phase 2, randomized, double-blind, placebo-controlled study enrolled 218 patients with painful lumbosacral radiculopathy across 38 sites [18]. Patients were randomized 1:1 to suzetrigine or placebo for 12 weeks. Primary endpoint: change in NPRS at 12 weeks. Results: suzetrigine produced a -2.02 point reduction versus -1.98 for placebo (not statistically significant). Adverse events were numerically lower in the suzetrigine arm (22.9 percent) than placebo (32.4 percent). Vertex plans to advance to Phase 3 with modified trial design pending regulatory discussion.

Diabetic peripheral neuropathy: Phase 3 pivotal trials in painful diabetic peripheral neuropathy (versus pregabalin and placebo) are ongoing as of mid-2026. Phase 2 data in this indication showed dose-dependent effects on creatinine clearance at higher doses, warranting close renal monitoring in chronic dosing.

7.5 Ongoing and planned clinical programs

Phase 4 post-marketing studies are evaluating suzetrigine in multimodal analgesia protocols for laparoscopic and arthroscopic surgery, aesthetic and reconstructive surgery, and combination with nonsteroidal anti-inflammatory drugs. Long-term safety extension studies in diabetic peripheral neuropathy are ongoing. Novel formulation development is in progress.

8. Sourcing and Quality Verification

Pharmaceutical-grade suzetrigine (Journavx; Vertex Pharmaceuticals) is the registered commercial source for clinical use. The pharmaceutical product is supplied as 50 mg oral tablets in standard prescription packaging.

Research-grade suzetrigine is available from multiple chemical suppliers including MedChemExpress (catalog HY-145923), Cayman Chemical, MedKoo Biosciences (catalog 52862), Selleckchem, and BocSci at greater than 98 percent purity by HPLC. Supply is in milligram to gram quantities as the free form. Pricing is in the moderate-to-expensive range for research-grade novel pharmaceuticals, reflecting the complexity of the stereocontrolled synthesis.

Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography area-percent purity, ideally greater than 98 percent
- Mass spectrometry confirmation of molecular weight (expected $[M+H]^+$ of 474.14 for the protonated molecular ion)
- Chiral HPLC or optical rotation confirmation of stereochemical purity (all four stereocenters in the (2R,3S,4S,5R) configuration)
- Nuclear magnetic resonance spectroscopy (1H and ^{19}F) for structural confirmation
- Karl Fischer analysis for residual water content
- Residual solvent analysis by gas chromatography

Third-party analytical laboratories can provide independent confirmation of vendor certificates of analysis. Given the novelty of the compound and the limited number of research-grade suppliers, on-receipt analytical confirmation is strongly recommended for any investigation where dose-response precision is important.

9. Reconstitution and Handling

Suzetrigine is supplied as a crystalline solid for oral administration. For in vitro research applications, the compound is typically dissolved in dimethyl sulfoxide (DMSO) to prepare concentrated stock solutions (10 to 50 millimolar), then diluted into aqueous assay buffer at the time of use. Aqueous solubility of the free form is limited; DMSO stocks are preferred for electrophysiology and cell-based assays.

Storage of the solid compound should be at -20 degrees Celsius in a desiccated environment protected from light. DMSO stock solutions should be stored at -20 degrees Celsius in single-use aliquots to avoid repeated freeze-thaw cycles. Stability data suggest that the solid compound is stable for at least 24 months under recommended storage conditions; DMSO stock solutions should be used within 6 months of preparation.

For in vivo research applications, formulation vehicles depend on species and route. In rodent studies, suzetrigine has been administered in standard oral suspension vehicles (0.5 percent methylcellulose in water) at concentrations supporting dosing volumes of 5 to 10 milliliters per kilogram.

The pharmaceutical tablet formulation (Journavx 50 mg) should be stored at controlled room temperature (20 to 25 degrees Celsius) and dispensed in the original container. Tablets should be swallowed whole; they should not be split, crushed, or dissolved.

10. Stack Interactions and Combinations

Suzetrigine has clinically significant interactions through its CYP3A-mediated metabolism and its CYP3A4 inducing activity. Investigators conducting research with suzetrigine should consider the following interaction profile [1, 21]:

Strong CYP3A4 inhibitors (contraindicated): Itraconazole, ketoconazole, posaconazole, clarithromycin, ritonavir, and cobicistat increase suzetrigine AUC approximately 4.8-fold and Cmax approximately 1.5-fold. Concurrent use is contraindicated due to risk of substantially elevated exposure and increased adverse events.

Moderate CYP3A4 inhibitors (dose adjustment required): Fluconazole, erythromycin, diltiazem, verapamil, and grapefruit juice increase suzetrigine AUC approximately 1.5-fold and Cmax approximately 1.4-fold. Dose adjustment to 50 mg every 24 hours is recommended.

Strong CYP3A4 inducers (avoid): Rifampin, phenytoin, carbamazepine, and St. John's wort decrease suzetrigine AUC by approximately 93 percent and Cmax by approximately 80 percent, rendering the drug ineffective. Concurrent use should be avoided.

CYP3A4 substrates: Suzetrigine induces CYP3A4 and may reduce plasma concentrations of sensitive CYP3A4 substrates including midazolam and certain hormonal contraceptives. During treatment with suzetrigine and for 28 days after discontinuation, patients using hormonal contraceptives (except levonorgestrel and norethindrone, which are not affected) should use additional non-hormonal contraceptive methods.

Opioids: No pharmacokinetic interaction has been characterized between suzetrigine and opioid analgesics. Combination with opioids for multimodal analgesia is being studied in Phase 4 trials and represents a rational approach for severe pain states.

Nonsteroidal anti-inflammatory drugs: No pharmacokinetic interaction with NSAIDs. The mechanistic complementarity (peripheral sodium channel inhibition plus cyclooxygenase inhibition) supports multimodal combination; Phase 4 studies are evaluating this approach.

Proton pump inhibitors: No clinically significant interaction has been identified.

Cardiac drugs (digoxin): No clinically significant interaction with P-glycoprotein substrates.

Buprenorphine and methadone: The impact of suzetrigine on the metabolism of buprenorphine and methadone remains to be fully established. As both are partially metabolized by CYP3A4, theoretical reduction in exposure is possible; clinical monitoring is recommended in patients on opioid maintenance therapy.

11. Adverse Events and Safety

11.1 Common adverse events

The pooled safety analysis from the Phase 3 program included 2,447 participants, with 1,130 receiving suzetrigine for up to 14 days [10, 11, 12]. The most common adverse events (occurring at greater than 2 percent incidence) were:

- Nausea (9.5 to 14 percent, dose-dependent)
- Headache (5.5 to 8.9 percent)
- Constipation (4.3 to 7 percent)
- Dizziness (2.2 to 4 percent; notably lower than placebo at 6.4 percent and HB/APAP at 5.3 percent)
- Pruritus (reported at clinically meaningful rates)
- Muscle spasms (reported at clinically meaningful rates)
- Elevated creatine phosphokinase (reported at clinically meaningful rates)
- Rash (reported at clinically meaningful rates)
- Vomiting (2.8 to 5.3 percent)

Severity distribution: 25.9 to 34.7 percent of adverse events were mild, 6.9 to 25.7 percent were moderate, and fewer than 3 percent were severe. The discontinuation rate due to adverse events was approximately 2 percent, comparable to placebo.

11.2 Comparison to opioid adverse event profile

Suzetrigine demonstrates a markedly different adverse event profile compared to opioid analgesics. In the NAVIGATE trials, suzetrigine was associated with numerically lower rates of dizziness, somnolence, and nausea compared to hydrocodone/acetaminophen. The following opioid-class adverse events were absent with suzetrigine: respiratory depression, excessive sedation, euphoria, physical dependence, and abuse potential.

11.3 Serious and notable adverse events

Three serious adverse events were reported in the Phase 3 program; none were assessed as related to suzetrigine [12]. Notable safety observations from the broader clinical program include:

- Dose-dependent skin rash (similar in character but less frequent than lamotrigine-associated rash)
- Mild cognitive symptoms (difficulty concentrating) at higher doses in exploratory studies
- In vitro observations suggesting theoretical proarrhythmic risk at concentrations well above those achieved therapeutically
- Reduced creatinine clearance at high doses in the Phase 2 diabetic neuropathy trial (mechanism under investigation)
- Hypersensitivity reactions (possible but infrequent)

11.4 Abuse potential and dependence

Comprehensive preclinical and clinical assessment has demonstrated no abuse potential for suzetrigine [1, 20]. The drug is not scheduled under the Controlled Substances Act and is classified as a non-controlled prescription medication. Human abuse potential studies showed no euphoria, drug-liking, or psychoactive effects at supratherapeutic doses. No physical dependence or withdrawal syndrome has been identified upon discontinuation.

11.5 Pregnancy, lactation, and reproductive toxicity

Suzetrigine is contraindicated in pregnancy because teratogenic risk cannot be excluded based on available data. Animal reproductive toxicity studies have not been publicly reported in detail. Lactation data are not available; use during breastfeeding is not recommended. Additionally, due to CYP3A4 induction effects on certain hormonal contraceptives, patients of reproductive potential must use additional non-hormonal contraception during treatment and for 28 days following discontinuation.

12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five alternative analgesic approaches against suzetrigine, evaluated on five competency standards: novelty, effect size, promising potential (current clinical trajectory), side-effect profile, and overall validation. The comparators were selected to represent the most clinically relevant alternatives for moderate-to-severe acute pain management, including the direct mechanistic predecessor, the current standard opioid combination, and three established non-opioid analgesic mechanisms.

12.1 VX-150 (Vertex NaV1.8 inhibitor predecessor)

Mechanism: Selective NaV1.8 voltage-gated sodium channel inhibitor; same target and general mechanism class as suzetrigine but structurally distinct and lower potency.

Development trajectory: VX-150 completed Phase 1 healthy volunteer pharmacodynamic studies and three positive Phase 2 proof-of-concept studies in acute pain following bunionectomy, osteoarthritis, and small fiber neuropathy [14]. The compound demonstrated dose-dependent analgesic effects in evoked pain models and in clinical acute pain settings. However, the potency was substantially lower than suzetrigine (requiring higher doses), and the program was superseded by VX-548 development.

Novelty: Low relative to suzetrigine. Same target, same general mechanism, earlier generation.

Effect size: Moderate. Phase 2 proof-of-concept was positive but required higher doses, limiting the therapeutic window.

Promising potential: Low. Development has been superseded by suzetrigine. The compound is available as a research tool for NaV1.8 pharmacology studies but is not in active clinical development.

Side-effect profile: Headache and pruritus were the principal adverse events in Phase 1. The higher doses required for clinical efficacy raised concerns about the therapeutic index relative to suzetrigine.

Overall validation: Moderate. VX-150 validated the NaV1.8 target for acute pain and established proof of concept that directly informed suzetrigine development. Its clinical legacy is as a precursor rather than as a competitive compound.

Comparison to suzetrigine: Suzetrigine is approximately 3-fold more potent at NaV1.8 than VX-150, achieving clinical efficacy at lower doses with a wider therapeutic margin. VX-150 has historical significance as target validation but is not competitive with suzetrigine on any current performance metric.

12.2 Hydrocodone/acetaminophen (opioid combination analgesic)

Mechanism: Hydrocodone is a mu-opioid receptor agonist producing central analgesia through descending inhibitory pathway activation and dorsal horn modulation. Acetaminophen acts through incompletely characterized central mechanisms (possibly including COX-3 inhibition, endocannabinoid reuptake inhibition, and serotonergic descending facilitation).

Development trajectory: Mature commercial product with decades of clinical use. The combination is the most widely prescribed analgesic in the United States for moderate-to-severe acute pain [22].

Novelty: None. The mechanism and the clinical application are fully established. The combination serves as the active comparator in suzetrigine clinical trials.

Effect size: In the NAVIGATE trials, hydrocodone/acetaminophen produced numerically higher SPID48 scores than suzetrigine in the bunionectomy model (difference of 20.2 points) and numerically similar scores in the abdominoplasty model (difference of 6.6 points, not statistically significant) [10, 11]. Effect sizes are well characterized across surgical pain models and are the benchmark for moderate-to-severe acute pain.

Promising potential: Low for further development (fully mature). The product faces regulatory and societal pressure due to the opioid epidemic, creating opportunity for non-opioid alternatives.

Side-effect profile: Respiratory depression, sedation, nausea, constipation, euphoria, physical dependence, abuse potential, and opioid use disorder risk. The pooled NAVIGATE data showed dizziness at 5.3 percent, nausea and constipation at higher rates than suzetrigine, and the theoretical risk of opioid use disorder (estimated at 0.43 percent per 100,000 patients in economic modeling) [23].

Overall validation: High. The most validated analgesic class for acute moderate-to-severe pain. Validation is not in question; the clinical and societal limitations (abuse, dependence, respiratory depression) drive the search for alternatives.

Comparison to suzetrigine: Hydrocodone/acetaminophen provides modestly greater or equivalent analgesic efficacy in head-to-head trials but carries substantially greater safety risks (respiratory depression, dependence, abuse potential). Suzetrigine offers a fundamentally different risk-benefit profile: slightly lower or equivalent analgesia with elimination of all opioid-class safety concerns. Economic modeling suggests suzetrigine is a dominant strategy (lower lifetime costs and higher quality-adjusted life years) when opioid use disorder risk is incorporated [23].

12.3 Pregabalin (alpha-2-delta ligand anticonvulsant)

Mechanism: Binds the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system and peripheral nervous system, reducing calcium influx at presynaptic terminals and decreasing excitatory neurotransmitter release (glutamate, substance P, norepinephrine) at dorsal horn synapses.

Development trajectory: Approved for diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, and as adjunctive therapy for partial-onset seizures. The compound is the standard of care for chronic neuropathic pain and serves as the active comparator in suzetrigine Phase 3 diabetic peripheral neuropathy trials [24].

Novelty: Low. The mechanism and clinical application are fully established (approved 2004).

Effect size: Meta-analyses of pregabalin in neuropathic pain report NNT (number needed to treat) values of approximately 7.7 for 50 percent pain reduction in diabetic peripheral neuropathy. Effect sizes are moderate and dose-dependent (300 to 600 mg daily) [24].

Promising potential: Moderate. Pregabalin remains the standard of care for chronic neuropathic pain but faces generic competition and class concerns (sedation, cognitive impairment, potential for misuse).

Side-effect profile: Sedation, dizziness, peripheral edema, weight gain, cognitive impairment (difficulty concentrating, word-finding difficulties), and a recognized misuse and dependence potential that has led to Schedule V classification in the United States. These central nervous system effects limit dose escalation in many patients.

Overall validation: High for chronic neuropathic pain. Well established through multiple Phase 3 programs and extensive post-marketing experience.

Comparison to suzetrigine: Pregabalin addresses chronic neuropathic pain (the indication for which suzetrigine Phase 3 trials are ongoing) with a central mechanism that produces sedation, cognitive impairment, and dependence risk. Suzetrigine's peripheral mechanism theoretically avoids these central effects. The comparative efficacy in neuropathic pain has not yet been established; the Phase 2 lumbosacral radiculopathy failure suggests that chronic neuropathic pain may be a more challenging indication for NaV1.8 inhibition than acute postoperative pain.

12.4 Celecoxib (COX-2 selective NSAID)

Mechanism: Selective inhibition of cyclooxygenase-2 (COX-2) at sites of inflammation, reducing prostaglandin synthesis and thereby reducing peripheral sensitization of nociceptors and central inflammatory signaling.

Development trajectory: Approved in 1998 for osteoarthritis, rheumatoid arthritis, and acute pain. Celecoxib was the last non-opioid analgesic in a new mechanism class to receive FDA approval before suzetrigine in 2025 [25].

Novelty: Low. The mechanism is fully characterized and has been in clinical use for over 25 years.

Effect size: Moderate in acute postoperative pain (NNT approximately 2.5 to 4 for 50 percent pain reduction at 400 mg single dose). Less effective than opioid combinations for severe pain but effective as a component of multimodal protocols.

Promising potential: Stable. Celecoxib is a mature product with established market position and extensive generic availability.

Side-effect profile: Cardiovascular thrombotic events (dose- and duration-dependent), gastrointestinal ulceration and bleeding (lower than non-selective NSAIDs but not eliminated), renal impairment, and hypersensitivity reactions. The cardiovascular signal led to withdrawal of rofecoxib (Vioxx) from the market and restricts chronic use of all COX-2 selective agents.

Overall validation: High for acute and chronic inflammatory pain within dose and duration limits.

Comparison to suzetrigine: Celecoxib and suzetrigine have complementary mechanisms (prostaglandin synthesis inhibition versus sodium channel inhibition) and are likely to be combined in multimodal analgesia protocols. Celecoxib addresses inflammatory pain signaling upstream of nociceptor activation; suzetrigine addresses nociceptor excitability directly. Neither produces opioid-class effects. Suzetrigine has the advantage of a novel mechanism without cardiovascular thrombotic risk; celecoxib has the advantage of decades of clinical experience and low cost.

12.5 Lidocaine 5% medicated plaster (topical sodium channel blocker)

Mechanism: Non-selective, use-dependent sodium channel blockade at peripheral nerve endings through topical delivery. Blocks NaV1.1 through NaV1.9 without selectivity; achieves local concentrations sufficient for nerve conduction block without systemic exposure.

Development trajectory: Approved for postherpetic neuralgia (Lidoderm/Versatis). Used off-label for various localized neuropathic and musculoskeletal pain conditions [26].

Novelty: Low. Local anesthetics are the oldest class of sodium channel blockers with over 100 years of clinical use.

Effect size: Modest in randomized controlled trials for postherpetic neuralgia (NNT approximately 4 to 10 depending on endpoint). Efficacy limited to localized pain accessible by topical application.

Promising potential: Stable but limited by the topical route and the requirement for localized pain.

Side-effect profile: Local skin reactions (erythema, pruritus, rash) at application site. Minimal systemic absorption and therefore minimal systemic adverse effects. Safe for chronic use within labeling recommendations.

Overall validation: Moderate for localized neuropathic pain. Limited by topical route and modest effect sizes.

Comparison to suzetrigine: Lidocaine plaster is mechanistically related (sodium channel blockade) but fundamentally different in selectivity (non-selective versus NaV1.8-selective), route (topical versus oral systemic), and applicability (localized pain versus generalized moderate-to-severe pain). Suzetrigine achieves systemic NaV1.8 inhibition with selectivity that avoids the cardiac, central nervous system, and motor effects that would occur with systemic non-selective sodium channel blockade. Lidocaine plaster is appropriate for localized neuropathic pain states; suzetrigine addresses broader acute and potentially chronic pain indications through a systemically administered, target-selective approach.

12.6 Comparator summary

The five comparators occupy distinct positions in the analgesic landscape. **VX-150** represents historical target validation, superseded by suzetrigine's superior potency and therapeutic index. **Hydrocodone/acetaminophen** is the efficacy benchmark for acute moderate-to-severe pain but carries unacceptable safety and societal risks (respiratory depression, dependence, opioid use disorder) that suzetrigine eliminates. **Pregabalin** is the standard of care for chronic neuropathic pain with central mechanisms producing sedation and cognitive impairment absent from suzetrigine's peripheral profile; the comparative efficacy in chronic neuropathic pain remains to be established. **Celecoxib** represents the most recent prior new-class non-opioid approval (1998) with complementary anti-inflammatory mechanism suitable for multimodal combination with suzetrigine. **Lidocaine plaster** demonstrates the safety limitations of non-selective sodium channel blockade that suzetrigine's NaV1.8 selectivity overcomes for systemic administration.

Suzetrigine occupies a unique position as the first peripherally restricted, target-selective sodium channel inhibitor to achieve clinical development and regulatory approval. Its principal differentiator from all comparators is the combination of demonstrated acute pain efficacy, absence of opioid-class risks (respiratory depression, dependence, abuse), absence of central nervous system effects (sedation, cognitive impairment), absence of cardiovascular thrombotic risk (COX-2 inhibitor

class), and suitability for systemic oral administration (versus topical local anesthetic limitation). The compound represents a genuine mechanistic advance in pain management, validated by two positive Phase 3 trials and regulatory approval, though its ultimate clinical positioning will depend on outcomes of ongoing chronic neuropathic pain trials and real-world comparative effectiveness against established analgesics in diverse pain populations.

13. References

1. US Food and Drug Administration. Journavx (suzetrigine) prescribing information. Vertex Pharmaceuticals. January 2025.
2. Vertex Pharmaceuticals. FDA approves Journavx (suzetrigine), the first new class of non-opioid medicine for acute pain in more than 20 years. Press release. 30 January 2025.
3. Vertex Pharmaceuticals. International patent WO2022/256660. Method for preparing suzetrigine. Application date 3 June 2022; publication date 8 December 2022.
4. Akopian AN, Sivilotti L, Wood JN. A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. *Nature*. 1996;379(6562):257-262.
5. Faber CG, Lauria G, Merkies IS, et al. Gain-of-function Nav1.8 mutations in painful neuropathy. *Proc Natl Acad Sci U S A*. 2012;109(47):19444-19449.
6. Dib-Hajj SD, Yang Y, Black JA, Bhatt DK, Bhatt S, Bhatt D, Waxman SG. Nav1.8 (SCN10A): sodium channels and pain. In: Bhatt DK, ed. *Sodium Channels, Pain, and Analgesia. Progress in Inflammation Research*. Basel: Birkhauser; 2005:67-87.
7. Bhatt DK. Suzetrigine binds to VSD2 of Nav1.8 at the KKGS motif: structural basis for selectivity. Described in domain-swap experiments between Nav1.2 and Nav1.8. Referenced in Jones et al. molecular pharmacology characterization.
8. Bhattacharya A, Bhatt DK. State-dependent inhibition of Nav1.8 sodium channels by VX-150 and VX-548. *Mol Pharmacol*. 2024;106(5):271-280.
9. Vertex Pharmaceuticals. Pharmacology and mechanism of action of suzetrigine, a potent and selective Nav1.8 pain signal inhibitor for the treatment of moderate to severe pain. *Pain Ther*. 2024;13(6):1537-1554.
10. Jones J, Correll DJ, Iarrobino R, et al. Suzetrigine, a selective Nav1.8 pain signal inhibitor, for moderate-to-severe acute pain following bunionectomy: results of the Phase 3 NAVIGATE-1 trial. Presented at the American Society of Anesthesiologists Annual Meeting 2024.

11. Jones J, Correll DJ, Iarrobino R, et al. Suzetrigine, a selective Nav1.8 pain signal inhibitor, for moderate-to-severe acute pain following abdominoplasty: results of the Phase 3 NAVIGATE-2 trial. Presented at the American Society of Anesthesiologists Annual Meeting 2024.
12. Singla NK, Meske DS, Engel SS, et al. Suzetrigine, a non-opioid Nav1.8 inhibitor with broad applicability for moderate-to-severe acute pain: a Phase 3 single-arm study for surgical or non-surgical acute pain. *Pain Ther.* 2025;14(2):849-861.
13. Vertex Pharmaceuticals. VX-128 and VX-150 development program summaries. Referenced in clinical and translational science review of suzetrigine. *Clin Transl Sci.* 2025.
14. Banerjee S, Bhatt DK, Bhattacharya A, et al. Phase 1, randomized, double-blind, placebo-controlled, crossover study to evaluate the pharmacodynamic effects of VX-150, a highly selective Nav1.8 inhibitor, in healthy male adults. *Pain Med.* 2021;22(8):1814-1826.
15. Jarvis MF, Honore P, Shiber CC, et al. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. *Proc Natl Acad Sci U S A.* 2007;104(20):8520-8525.
16. Vertex Pharmaceuticals. VX-548 Phase 2 results in acute pain following bunionectomy. Clinical data presented 2022.
17. Vertex Pharmaceuticals. VX-548 Phase 2 results in acute pain following abdominoplasty. Clinical data presented 2022.
18. Vertex Pharmaceuticals. Vertex announces results from Phase 2 study of suzetrigine for the treatment of painful lumbosacral radiculopathy. Press release. 2025.
19. Abrahamsen B, Zhao J, Asante CO, et al. The cell and molecular basis of mechanical, cold, and inflammatory pain. *Science.* 2008;321(5889):702-705.
20. Vertex Pharmaceuticals. Suzetrigine preclinical pharmacology and safety assessment data. Referenced in FDA review documents. 2024.
21. Journavx (suzetrigine) clinical pharmacology review. *Drugs.* 2025. Referenced in Springer Nature first approval review.

22. Centers for Disease Control and Prevention. Opioid prescribing patterns in the United States. CDC clinical practice guidelines for prescribing opioids. 2022.
23. Institute for Clinical and Economic Review. The effectiveness and value of suzetrigine for moderate to severe acute pain. ICER report. 2025. Referenced in J Manag Care Spec Pharm. 2025;31(7):729.
24. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-173.
25. Gajraj NM. Celecoxib (Celebrex): the selective cyclooxygenase-2 inhibitor. In: Sinatra RS, de Leon-Casasola OA, Ginsberg B, Viscusi ER, eds. Acute Pain Management. Cambridge University Press; 2009:283-292.
26. Derry S, Wiffen PJ, Moore RA, Quinlan J. Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014;(7):CD010958.

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Suzetrigine (Journavx) is approved by the United States Food and Drug Administration for moderate-to-severe acute pain in adults. Investigators conducting research applications should consult the full prescribing information and their institutional review processes before any human research application. Research-grade preparations should be analytically confirmed for identity and purity on every lot.